Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 12 | 2025 | 1273 | 1.290 |
Why?
|
| Sinus Thrombosis, Intracranial | 2 | 2024 | 49 | 1.030 |
Why?
|
| Pulmonary Edema | 1 | 2025 | 54 | 0.900 |
Why?
|
| Rituximab | 2 | 2025 | 171 | 0.890 |
Why?
|
| Immunologic Factors | 1 | 2025 | 190 | 0.830 |
Why?
|
| Neoplasms | 4 | 2025 | 2974 | 0.760 |
Why?
|
| Tracheostomy | 1 | 2024 | 210 | 0.720 |
Why?
|
| Graft Rejection | 1 | 2025 | 556 | 0.700 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 313 | 0.680 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 950 | 0.650 |
Why?
|
| Anemia, Sickle Cell | 4 | 2026 | 332 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 977 | 0.610 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 870 | 0.510 |
Why?
|
| Lung Diseases | 3 | 2025 | 397 | 0.480 |
Why?
|
| Child, Preschool | 17 | 2026 | 15005 | 0.450 |
Why?
|
| Infant | 15 | 2025 | 13266 | 0.430 |
Why?
|
| Hemorrhage | 4 | 2025 | 485 | 0.420 |
Why?
|
| Tranexamic Acid | 2 | 2025 | 30 | 0.410 |
Why?
|
| Antifibrinolytic Agents | 2 | 2025 | 46 | 0.410 |
Why?
|
| Retrospective Studies | 18 | 2026 | 17538 | 0.390 |
Why?
|
| Child | 22 | 2026 | 26171 | 0.380 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2025 | 683 | 0.380 |
Why?
|
| Adolescent | 17 | 2026 | 20797 | 0.380 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2023 | 49 | 0.360 |
Why?
|
| Warts | 2 | 2022 | 17 | 0.360 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2107 | 0.350 |
Why?
|
| Graft vs Host Disease | 4 | 2024 | 688 | 0.330 |
Why?
|
| Neutropenia | 2 | 2022 | 209 | 0.320 |
Why?
|
| Neuroblastoma | 2 | 2025 | 547 | 0.310 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5164 | 0.260 |
Why?
|
| Prognosis | 3 | 2025 | 4845 | 0.250 |
Why?
|
| Acute Chest Syndrome | 1 | 2026 | 14 | 0.240 |
Why?
|
| Male | 16 | 2026 | 64375 | 0.240 |
Why?
|
| Female | 16 | 2026 | 70227 | 0.230 |
Why?
|
| Humans | 28 | 2026 | 130055 | 0.220 |
Why?
|
| Pericardial Effusion | 1 | 2025 | 72 | 0.220 |
Why?
|
| Fatal Outcome | 1 | 2025 | 356 | 0.220 |
Why?
|
| Interleukin-15 | 1 | 2025 | 104 | 0.210 |
Why?
|
| Stem Cell Transplantation | 1 | 2025 | 224 | 0.210 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 26 | 0.200 |
Why?
|
| Anticoagulants | 2 | 2024 | 598 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2025 | 3114 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 57 | 0.190 |
Why?
|
| Lymphopenia | 1 | 2022 | 33 | 0.180 |
Why?
|
| Postpartum Hemorrhage | 1 | 2023 | 110 | 0.180 |
Why?
|
| Agammaglobulinemia | 1 | 2022 | 42 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 500 | 0.170 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2020 | 12 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2024 | 5033 | 0.160 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 211 | 0.160 |
Why?
|
| Kidney Transplantation | 1 | 2025 | 552 | 0.160 |
Why?
|
| Ribosomal Proteins | 1 | 2020 | 70 | 0.160 |
Why?
|
| Incidence | 2 | 2025 | 3321 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 565 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 306 | 0.140 |
Why?
|
| Lung | 2 | 2024 | 1531 | 0.140 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 360 | 0.140 |
Why?
|
| Transplantation Conditioning | 3 | 2023 | 327 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2025 | 497 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 1059 | 0.110 |
Why?
|
| Young Adult | 5 | 2026 | 9978 | 0.100 |
Why?
|
| Transplantation, Autologous | 2 | 2025 | 253 | 0.100 |
Why?
|
| Alemtuzumab | 2 | 2023 | 89 | 0.090 |
Why?
|
| Respiratory Insufficiency | 2 | 2025 | 245 | 0.090 |
Why?
|
| Receptors, CXCR4 | 2 | 2022 | 69 | 0.090 |
Why?
|
| Developing Countries | 1 | 2012 | 303 | 0.080 |
Why?
|
| Activated Protein C Resistance | 1 | 2009 | 2 | 0.080 |
Why?
|
| Factor V | 1 | 2009 | 15 | 0.080 |
Why?
|
| Renal Veins | 1 | 2009 | 31 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 63 | 0.070 |
Why?
|
| Thrombophilia | 1 | 2009 | 41 | 0.070 |
Why?
|
| Lipoprotein(a) | 1 | 2009 | 139 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 164 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2025 | 8547 | 0.070 |
Why?
|
| Epilepsy | 1 | 2012 | 864 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 68 | 0.050 |
Why?
|
| Texas | 2 | 2025 | 3655 | 0.050 |
Why?
|
| Israel | 1 | 2024 | 44 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2025 | 192 | 0.050 |
Why?
|
| Transfusion Reaction | 1 | 2024 | 42 | 0.050 |
Why?
|
| Gangliosides | 1 | 2025 | 72 | 0.050 |
Why?
|
| United States | 3 | 2025 | 11893 | 0.050 |
Why?
|
| Europe | 1 | 2025 | 363 | 0.050 |
Why?
|
| Hemolysis | 1 | 2024 | 86 | 0.050 |
Why?
|
| Natural Killer T-Cells | 1 | 2025 | 91 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 51 | 0.050 |
Why?
|
| Autopsy | 1 | 2023 | 113 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 10956 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 668 | 0.040 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2021 | 72 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2026 | 2076 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 425 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 521 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1240 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2290 | 0.040 |
Why?
|
| Penetrance | 1 | 2020 | 107 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2025 | 12821 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2020 | 716 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 430 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1057 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2026 | 3026 | 0.030 |
Why?
|
| Pedigree | 1 | 2020 | 1670 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 2392 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2191 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1264 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1325 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 611 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3358 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 20816 | 0.020 |
Why?
|
| Lebanon | 1 | 2012 | 10 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6401 | 0.020 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2012 | 92 | 0.020 |
Why?
|
| Heart Failure | 1 | 2024 | 2325 | 0.020 |
Why?
|
| Hematuria | 1 | 2009 | 48 | 0.020 |
Why?
|
| Point Mutation | 1 | 2009 | 332 | 0.020 |
Why?
|
| Heparin | 1 | 2009 | 205 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 533 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 942 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 920 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 2587 | 0.010 |
Why?
|
| Middle Aged | 1 | 2022 | 28303 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 30999 | 0.010 |
Why?
|